



ASX ANNOUNCEMENT

New Chief Financial Officer appointed

25 August 2021 – Cann Group Limited (ASX: CAN) (**Cann**) today advised that its Chief Financial Officer (CFO), Greg Bullock, will be leaving his role and that Deborah Ambrosini has been appointed to the role of CFO, with effect from 1 September 2021.

Ms Ambrosini brings significant experience as a CFO and in senior finance roles with ASX-listed companies and was most recently CFO and Company Secretary with listed pharmaceutical company, Acrux Limited (ASX:ACR). Ms Ambrosini has also held CFO and senior finance and management roles in the health, technology and resources sectors and has a broad skillset that extends into business strategy, contract negotiations and investor relations.

Cann CEO, Peter Crock, said “Deborah joins the company at a time when we can take full advantage of her experience and business insight. She is a strong addition to our senior management team and will be an important contributor as we continue to execute on our growth plans.”

“I would also like to acknowledge Greg Bullock’s contribution to the business during his time as CFO. Greg was instrumental in helping us secure our bank and equity financing, and introduced strong financial disciplines into the business. We wish him every success in his next role.”

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock CEO Cann Group Limited +61 3 9095 7088 contact@canngrouponlimited.com	Clive Fanning Head of Investor Relations Cann Group Limited +61 3 9095 7088 clive.fanning@canngrouponlimited.com
---	--

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com

Cann Group Limited
ACN 603 949 739
4 Research Avenue, Bundoora, VIC 3083 Australia
Ph: +61 3 9095 7088